title: The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
abstract: The adverse events (AEs) of oxycodone in cancer-related pain were controversial, so we conducted a meta-analysis to determine it. PubMed, Embase, CBM, CNKI, WanFang database, The Cochrane library, Web of Science, and the reference of included studies were searched to recognize pertinent studies. Relative risk (RR) with 95% confidence intervals (CIs) for all AEs were all extracted. The fixed-effects model was used to calculate pooled RRs and 95% CIs. Power calculation was performed using macro embedded in SAS software after all syntheses were completed. We identified 11 eligible trials involving 1211 patients: 604 patients included in oxycodone group and 607 patients involved in control group. Our quantitative analysis included 8 AEs, and the pooled analyses indicated that oxycodone compared with other opioids in cancer-related pain were not significantly decreased RRs of all AEs (dizziness RR = 0.94, 95% CI: 0.69-1.30, Z = 0.35, P = 0.72; nausea RR = 0.88, 95% CI: 0.72-1.07, Z = 1.26, P = 0.21; vomiting RR = 0.89, 95% CI: 0.70-1.15, Z = 0.9, P = 0.37; sleepiness RR = 0.86, 95% CI: 0.38-1.36, Z = 0.36, P = 0.72; constipation RR = 0.98, 95% CI: 0.81-1.19, Z = 0.21, P = 0.83; anorexia RR = 0.97, 95% CI = 0.58-1.62, Z = 0.11, P = 0.91; pruritus RR = 0.76, 95% CI: 0.44-1.30, Z = 1.01, P = 0.31; dysuria RR = 0.33, 95% CI: 0.07-1.62, Z = 1.36, P = 0.1)]. The subgroup analysis shown that Ox controlled-release (CR) had less sleepiness compared with MS-contin (Mc) CR (RR = 0.47, 95% CI: 0.25-0.90, P = 0.02). The power analysis suggests that all AEs have low statistical power. The present meta-analysis detected that no statistically significant difference were found among oxycodone and other opioids in all AEs, but Ox CR may had less sleepiness compared with Mc CR when subgroup analysis were conducted.
authors.affiliation: From the Department of Oncology, Affiliated Hospital of Zunyi Medical University (HM, LH, G-JY, J-GZ); Center for Translational Medicine (HM, LH, J-GZ) and Department of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry of Education (YL), Zunyi Medical University; Department of Cardiology and Endodontics, Affiliated Stomatological Hospital of Zunyi Medical University (S-HJ), Zunyi; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University (X-TZ); Center for Evidence-Based and Translational Medicine, Wuhan University (X-TZ), Wuhan; Graduate College and School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin (XT), China.
authors.forename: Hu
authors.initials: H
authors.lastname: Ma
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Lang
authors.initials: L
authors.lastname: Huang
authors.forename: Xian-Tao
authors.initials: XT
authors.lastname: Zeng
authors.forename: Su-Han
authors.initials: SH
authors.lastname: Jin
authors.forename: Guo-Jun
authors.initials: GJ
authors.lastname: Yue
authors.forename: Xu
authors.initials: X
authors.lastname: Tian
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Zhou
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010098:Oxycodone / Q000009:adverse effects* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010098:Oxycodone